Biomarkers in idiopathic pulmonary fibrosis: Current insight and future direction

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease with a dismal prognosis. Early diagnosis, accurate prognosis, and personalized therapeutic interventions are essential for improving patient outcomes. Biomarkers, as measurable indicators of biological processes or disease states, hold significant promise in IPF management. In recent years, there has been a growing interest in identifying and validating biomarkers for IPF, encompassing various molecular, imaging, and clinical approaches. This review provides an in-depth examination of the current landscape of IPF biomarker research, highlighting their potential applications in disease diagnosis, prognosis, and treatment response. Additionally, the challenges and future perspectives of biomarker integration into clinical practice for precision medicine in IPF are discussed.

Keywords: Biomarker; Diagnosis; Idiopathic pulmonary fibrosis; Prognosis; Treatment.

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

Ni S, Song M, Guo W, Guo T, Shen Q, Peng H. Ni S, et al. Expert Rev Respir Med. 2020 Jun;14(6):593-602. doi: 10.1080/17476348.2020.1745066. Epub 2020 Apr 12. Expert Rev Respir Med. 2020. PMID: 32187497 Review.

Wang Q, Xie Z, Wan N, Yang L, Jin Z, Jin F, Huang Z, Chen M, Wang H, Feng J. Wang Q, et al. Chin Med J (Engl). 2023 Jun 5;136(11):1278-1290. doi: 10.1097/CM9.0000000000002171. Chin Med J (Engl). 2023. PMID: 37130223 Free PMC article. Review.

Bartold K, Iskierko Z, Sharma PS, Lin HY, Kutner W. Bartold K, et al. Biomed J. 2024 Aug;47(4):100729. doi: 10.1016/j.bj.2024.100729. Epub 2024 Apr 22. Biomed J. 2024. PMID: 38657859 Free PMC article. Review.

Elhai M, Avouac J, Allanore Y. Elhai M, et al. Semin Arthritis Rheum. 2020 Jun;50(3):480-491. doi: 10.1016/j.semarthrit.2020.01.006. Epub 2020 Jan 28. Semin Arthritis Rheum. 2020. PMID: 32089354

Yang F, Wendusubilige, Kong J, Zong Y, Wang M, Jing C, Ma Z, Li W, Cao R, Jing S, Gao J, Li W, Wang J. Yang F, et al. EPMA J. 2023 Jul 31;14(3):417-442. doi: 10.1007/s13167-023-00334-4. eCollection 2023 Sep. EPMA J. 2023. PMID: 37605652 Free PMC article.

Cited by

Zhu C, Weng Q, Gao S, Li F, Li Z, Wu Y, Wu Y, Li M, Zhao Y, Han Y, Lu W, Qin Z, Yu F, Lou J, Ying S, Shen H, Chen Z, Li W. Zhu C, et al. Cell Death Dis. 2024 Aug 30;15(8):637. doi: 10.1038/s41419-024-07029-2. Cell Death Dis. 2024. PMID: 39214980 Free PMC article.

Wang Z, Zhang Z, Zhu L, Hou J, Fu H, Yang X, Wang F, Chen J. Wang Z, et al. BMC Pulm Med. 2024 Jul 19;24(1):352. doi: 10.1186/s12890-024-03172-w. BMC Pulm Med. 2024. PMID: 39030536 Free PMC article.

References

    1. Martinez FJ, Collard HR, Pardo A, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;3:17074. doi: 10.1038/nrdp.2017.74. - DOI - PubMed
    1. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;379:797–798. doi: 10.1056/NEJMc1807508. - DOI - PubMed
    1. Drakopanagiotakis F, Wujak L, Wygrecka M, Markart P. Biomarkers in idiopathic pulmonary fibrosis. Matrix Biol. 2018;68-69:404–421. doi: 10.1016/j.matbio.2018.01.023. - DOI - PubMed
    1. Stainer A, Faverio P, Busnelli S, et al. Molecular biomarkers in idiopathic pulmonary fibrosis: state of the art and future directions. Int J Mol Sci. 2021;22:6255. doi: 10.3390/ijms22126255. - DOI - PMC - PubMed
    1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824. doi: 10.1164/rccm.2009-040GL. - DOI - PMC - PubMed